GENE ONLINE|News &
Opinion
Blog

2022-12-29| In-DepthSpecial

64th ASH Annual Meeting and Exposition: Standard Treatments Face Challenges

by Justine Zhu
Share To
Standard treatments face challenges with new evidence. This time at the 64th ASH meeting, two drugs for blood cancers, Blinatumomab and Zanubrutinib, revealed their latest data from clinical trials in the Selected Latest Breaking Abstract section. It also presents the early results of the first-in-class drug Iptacopan for the rare disease paroxysmal nocturnal hemoglobinuria. One of the speeches in this session gave a good example. Dr. Saskia Middeldorp presented that heparin has no benefit in raising the live birth rate in inherited thrombophilia women with recurrent miscarriages. Previously, heparin injection was a standard treatment for women with recurrent miscarriage inherited thrombophilia, but without randomized controlled studies to prove the effectiveness.

GO Prime with only $1.49 now

LATEST
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Scroll to Top